S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
Log in

OTCMKTS:CPHRF - Cipher Pharmaceuticals Stock Price, Forecast & News

$0.87
+0.17 (+24.35 %)
(As of 12/10/2019 04:00 PM ET)
Today's Range
$0.87
Now: $0.87
$0.87
50-Day Range
$0.70
MA: $0.89
$0.96
52-Week Range
$0.70
Now: $0.87
$1.52
Volume3,000 shs
Average Volume4,524 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients. It also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Ozenoxacin to treat adult and paediatric patients with impetigo. In addition, the company has various commercial and pipeline hospital products administered in the acute care setting. Its pipeline products include Dermadexin and Pruridexin for the treatment of common chronic conditions; CF101 for the treatment of plaque psoriasis and rheumatoid arthritis; DTR-001 that is in pre-clinical stage of development for the removal or reduction of the appearance of tattoos; and ASF-1096, an orphan drug indication for the treatment of anorectal indications. Cipher Pharmaceuticals Inc. has a licensing agreement with Synergy Pharmaceuticals Inc. for developing, marketing, distributing, and selling TRULANCE (plecanatide). The company was founded in 2004 and is headquartered in Mississauga, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CPHRF
Previous SymbolNASDAQ:CPHR
CUSIPN/A
CIKN/A
Phone+1-905-6025840

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CPHRF News and Ratings via Email

Sign-up to receive the latest news and ratings for CPHRF and its competitors with MarketBeat's FREE daily newsletter.


Cipher Pharmaceuticals (OTCMKTS:CPHRF) Frequently Asked Questions

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CPHRF."

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc (OTCMKTS:CPHRF) announced its quarterly earnings results on Thursday, May, 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.06. The company earned $9.10 million during the quarter, compared to analysts' expectations of $10.87 million. View Cipher Pharmaceuticals' Earnings History.

What price target have analysts set for CPHRF?

1 Wall Street analysts have issued 12 month target prices for Cipher Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Cipher Pharmaceuticals' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 360.7% from the stock's current price. View Analyst Price Targets for Cipher Pharmaceuticals.

What is the consensus analysts' recommendation for Cipher Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cipher Pharmaceuticals.

Has Cipher Pharmaceuticals been receiving favorable news coverage?

Media coverage about CPHRF stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cipher Pharmaceuticals earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Cipher Pharmaceuticals.

Who are some of Cipher Pharmaceuticals' key competitors?

What other stocks do shareholders of Cipher Pharmaceuticals own?

Who are Cipher Pharmaceuticals' key executives?

Cipher Pharmaceuticals' management team includes the folowing people:
  • Mr. Robert D. Tessarolo, Pres, CEO & Director (Age 51)
  • Mr. Stephen L. Lemieux, CFO & Sec.
  • Mr. Chris Watters, VP of Corp. Devel.
  • Dr. Diane Gajewczyk, VP of Scientific & Medical Affairs
  • Mr. Norman Evans, Consultant (Age 64)

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPHRF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cipher Pharmaceuticals' stock price today?

One share of CPHRF stock can currently be purchased for approximately $0.87.

What is Cipher Pharmaceuticals' official website?

The official website for Cipher Pharmaceuticals is http://www.cipherpharma.com/.

How can I contact Cipher Pharmaceuticals?

Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company can be reached via phone at +1-905-6025840.


MarketBeat Community Rating for Cipher Pharmaceuticals (OTCMKTS CPHRF)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  163
MarketBeat's community ratings are surveys of what our community members think about Cipher Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPHRF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPHRF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: Return on Investment (ROI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel